It was a pleasure to catch up with our Editorial Board member Prof. Farhad Hafezi (ELZA Institute, Zurich, Switzerland), the winner of the ESCRS 2020 Refractive Award! Here he discusses the PACK-CXL multicentre trial, and the benefits of this treatment.
Questions
- Which patients are likely to benefit most from photoactivated chromophore for keratitis-corneal collagen cross-linking (PACK-CXL) treatment and in whom is it contraindicated? (00:06)
- How do you think that this treatment modality will translate into modern ophthalmology? (01:56)
- Do you think that PACK-CXL will replace antimicrobials in the future? (03:36)
Speaker Disclosures: Prof. Farhad Hafezi holds patents and applications fo corneal apparatus used for CXL, chromophore for CXL application; and is a shareholder and investor for EMAGine AG.
Support: Interview and filming supported by Touch Medical Media Ltd.
Filmed in coverage of ESCRS 2020.
